Novartis AG has made big changes to its oncology research organization in recent months, as the company looks to recapture lost ground in the immuno-oncology field, and Chief Medical Officer Vasant Narasimhan said in an interview the changes are all part of a “rejuvenation.”
There have been some high-profile R&D departures too, most notably the head of global oncology development Alessandro Riva, who was...




